You just read:

Boehringer Ingelheim and Lilly present full results from EASE Phase III program for empagliflozin as adjunct to insulin in type 1 diabetes

News provided by

Eli Lilly and Company , Boehringer Ingelheim

Oct 04, 2018, 06:30 ET